ASCEPT Tony Smith Quality Use of Medicines Award

Details of award	The ASCEPT Tony Smith Quality Use of Medicines (QUM) Award was established in memory of Emeritus Professor Anthony ("Tony") Smith AM, a pioneering clinical pharmacologist and internationally recognised leader in QUM. It is awarded annually for a submission that best demonstrates excellence in QUM research.
Eligibility criteria	• Financial member of ASCEPT. • Applicants for the Award must have been ASCEPT members for at least the previous 2 years, or if a valid interruption to membership exists, have been a member of ASCEPT for at least 2 years prior to the suspension of membership. • Applicants should have completed not less than two years and not more than eight years in employment since obtaining their highest tertiary qualification, allowing for career disruptions, or be within 8 years of completing Basic Physician Training. There is no age limit. • Past winners are not eligible to re-apply.
Application	Applicants must email their Application Package (in PDF format) to ascept@ascept.org by the specified deadline. An integral component of the Application Package is a description of how the research addresses an aspect(s) of QUM and the contribution made by the applicant to that research. **The ASCEPT Tony Smith Quality Use of Medicines Award Application Package should include:** a) Presentation abstract. Abstracts must be submitted using the Abstract Submission Template. b) Relevance of the study to QUM: up to 500-word description of how the research addresses an area of QUM, highlighting the importance and/or potential impact of the work and placing it in a broader health context. c) A recent CV (no more than 2 pages), plus any relevant details regarding career disruption (not included in page limit). d) Endorsement by applicant's Head of School, Supervisor of Training or equivalent to confirm that the applicant meets the award eligibility criteria and was a major contributor to the project outlined in the description.
Selection process	Applications will be assessed by an ASCEPT Board-appointed judging panel led by the Chair of the Clinical Pharmacology Special Interest Group or a delegated

<table>
<tr><td></td><td>representative and will include at least one ASCEPT Board member. The judging panel will be assembled in accordance with the ASCEPT Equity, Diversity and Inclusion Policy and any real or perceived conflicts of interests will be declared and recorded.

The application will be assessed according to the following criteria:

<table>
<tr><th>Criterion</th><th>Weight (%)</th></tr>
<tr><td>Scientific quality, innovation and significance, taking into account:
1. Knowledge of the area and understanding of the research
2. Evidence of innovation and thought leadership
3. Outcomes and significance of the work</td><td>80%</td></tr>
<tr><td>CV / Track record of applicant</td><td>20%</td></tr>
<tr><td>Total</td><td>100%</td></tr>
</table>
</td></tr>
<tr><td>Award</td><td>An official notification letter from the President will be sent to the successful candidate.

In 2026, the recipient will be offered the opportunity to speak at an online event in November or December.

The winner of the ASCEPT Tony Smith Quality Use of Medicines Award will also be invited to attend Science and Technology Australia’s Science Meets Parliament event in the following year, generously sponsored by Therapeutic Guidelines.</td></tr>
<tr><td>Enquires</td><td>Please direct any enquires to ascept@ascept.org</td></tr>
</table>